PharmaLink has partnered with Recall Results on an accurate and responsive process for drug recalls, withdrawals and market actions in the pharmaceutical industry.
The collaboration combines PharmaLink’s pharmaceutical returns processing expertise with Recall Results’ knowledge and advanced technologies for managing complex recalls.
It will focus on the development of integrated systems to streamline the process of recalls, supporting recalls of any class to the patient level. It aims to cut down the time to identify and respond to potentially harmful pharma products in the market.
With a focus on patient safety and compliance, the two companies are set to establish new standards in recall management.
PharmaLink CEO Thierry Beckers stated: “Through this partnership, PharmaLink offers comprehensive services for the notification, product retrieval, processing, storage and disposal of recalled products from the healthcare supply chain.
“We could not be more excited about the launch of this strategic partnership and the solutions it brings to our clients.
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Your download email will arrive shortly
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalData
“This partnership with Recall Results represents a significant step towards enhancing the safety standards in our industry. Together, we are poised to make a substantial impact in protecting public health.”
Specific initiatives and programmes from the PharmaLink-Recall Results partnership are anticipated during 2024.
Recall Results president and CEO John McFerron stated: “The collaboration with PharmaLink represents an exciting convergence of knowledge and capabilities.
“By integrating our sophisticated recall management solutions with PharmaLink’s pharmaceutical returns expertise, we will realise our shared vision for a safer pharmaceutical environment.”
